Clinical trial
Effects of Atomoxetine on Cognitive Function in Schizophrenia
NCT00420498 · Yale University, Other · Completed
Key facts
| NCT number | NCT00420498 |
|---|---|
| Title | Effects of Atomoxetine on Cognitive Function in Schizophrenia |
| Official title | Effects of Atomoxetine on Cognitive Function in Schizophrenia |
| Lead sponsor | Yale University, Other |
| Collaborators | National Alliance for Research on Schizophrenia and Depression |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia, Cognition, Smoking |
| Intervention type | Drug |
| Interventions | Atomoxetine (Strattera™) |
| Enrollment | 12 |
| Start date | Aug 1, 2005 |
| Completion | Sep 1, 2007 |
| First posted | Jan 11, 2007 |
| Last update posted | Dec 12, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: